UNSPSC 51382406: Diflumidone sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10F2NO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2NLB7019Y0, chemically known as 3-benzoyl-1,1-difluoromethanesulfonanilide sodium salt but more generally known as diflumidone sodium, which bears US NIH Compound Identifier 31500. Most nations, for tariff and trade purposes, schedule diflumidone sodium under HS 29350090 and SITC 51580. As of Q4 2014, DIFLUMIDONE SODIUM remains US FDA's Preferred Term for this commodity.

SMILES: C1CCC(CC1)C(=O)C2CCCC(C2)[N-]S(=O)(=O)C(F)F.[NA+].

UNSPSC 51382406 Diflumidone sodium is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The recent opportunities posted under this code—Seminole County's IFB for naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products—do not involve diflumidone sodium procurement. State and local governments appear to use this code for broader pharmaceutical and medical supply categories rather than for this specific active pharmaceutical ingredient. When procurement activity does surface under the code, it reflects health departments and cooperative purchasing alliances sourcing finished pharmaceutical products, medical countermeasures, and OTC items through RFPs, RFQs, and IBFs with multiple authorized wholesalers and manufacturers.

The issuing-body mix spans county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles such as MMCAP. Geographic activity in recent postings includes Florida, Texas, Minnesota, and Oregon through cooperative arrangements, but no solicitations in the source material explicitly target diflumidone sodium itself. The mismatch between the code's chemical-compound name and the transactional reality of state and local pharmaceutical procurement—which groups products by therapeutic class, NDC code, generic designation, and wholesale distribution tier rather than by active ingredient—suggests this code sees little relevant activity or that issuers misapply it when tagging pharmaceutical supply contracts. Firms pursuing pharmaceutical manufacturing or distribution to state and local buyers should monitor higher-level UNSPSC family codes covering pharmaceutical products and services (such as 51300000-level families) rather than rely on this specific commodity designation.